EBS Emergent BioSolutions Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%
Returns
ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x
Cash quality & payout
Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $742.90M | $1.04B |
| Cost of revenue | $326.20M | $681.30M |
| Gross profit | $416.70M | $362.30M |
| R&D expense | $53.20M | $70.70M |
| SG&A expense | $186.10M | $308.00M |
| Operating income | $100.10M | -$108.70M |
| Interest expense | $59.30M | $71.00M |
| Pretax income | $82.80M | -$142.90M |
| Income tax | $30.20M | $47.70M |
| Net income | $52.60M | -$190.60M |
| EBITDA | $195.90M | $100,000 |
| EPS (basic) | 0.98 | -3.60 |
| EPS (diluted) | 0.93 | -3.60 |
| Weighted avg. shares (diluted) | 56.70M | 53.00M |
| Balance sheet | ||
| Cash & equivalents | $205.40M | $105.60M |
| Receivables | $84.20M | $154.50M |
| Inventory | $343.40M | $311.70M |
| Current assets | $662.50M | $598.70M |
| PP&E, net | $205.40M | $270.60M |
| Goodwill | $0 | $0 |
| Intangibles | $436.50M | $501.50M |
| Total assets | $1.32B | $1.39B |
| Current liabilities | $132.20M | $162.40M |
| Short-term debt | — | $0 |
| Long-term debt | $572.10M | $663.70M |
| Total debt | $572.10M | $663.70M |
| Total liabilities | $796.00M | $906.90M |
| Shareholders' equity | $522.60M | $482.80M |
| Net debt | $366.70M | $558.10M |
| Shares outstanding | 52.10M | 54.30M |
| Cash flow statement | ||
| Operating cash flow | $170.60M | $58.70M |
| Capital expenditure | $13.80M | $22.90M |
| Free cash flow | $156.80M | $35.80M |
| Investing cash flow | $69.40M | $125.20M |
| Financing cash flow | -$136.60M | -$190.00M |
| Depreciation & amortization | $95.80M | $108.80M |
| Stock-based compensation | $16.20M | $18.00M |
| Share buybacks | $24.90M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.